Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

US10221455B2 · kind B2 · utility

Assignees

• BIOVERATIV THERAPEUTICS INC. · US
• PUGET SOUND BLOOD CENTER · US

Inventors

• Haiyan Jiang · Belmont, US
• Tongyao Liu · Lexington, US
• Sriram Krishnamoorthy · Medford, US
• Neil Josephson · Seattle, US
• Glenn Pierce · Cambridge, US

Key dates

• Filing date: Jan 12, 2013
• Grant date: Mar 5, 2019
• Expiry date: Nov 21, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/156
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.